Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q3 2020 · 10-Q
Revenue$1.19M$1.19M+403.4% vs Q3 2019 Net Income-$35.43M-$35.43MN/M vs Q3 2019 EPS Diluted-$0.04-$0.04N/M vs Q3 2019 Operating Income-$35,875,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,031,000N/M Margins · derivedOperating margin-3007.1%+13921.6 pt vs Q3 2019
Net margin-2970.0%+13613.1 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end